Nurse-led Family and Network Consultations (CARES)

Nurse-led Family and Network Consultations - Addressing Cancer-Related Symptoms and Concerns in Patients With High-grade Glioma and Their Families and Network (CARES)

Patients diagnosed with high-grade gliomas (HGG) experience a complex symptom burden including high-levels concerns.

As a consequence to this life-threatening disease, the rely on close contact with a specialized neuro-oncological team as well as support and practical assistance from their families. However, multidimensional burden of caregivers has been reported.

CARES seeks to facilitate and activate the existing resources within the patient and the network using a new model of systematic family care approach.

Specialized neuro-oncological nurses are responsible for an expanded area providing an opportunity for the nursing profession to establish a new model of nursing care. This may not only benefit the patients and their families but also contribute to strengthen the nurses' professional identity and support further development of neuro-oncological specialist team.

Study Overview

• Status: Completed
• Conditions: High-grade Glioma
• Intervention / Treatment: Behavioral: Family and Network Consultations

Detailed Description

Objectives To explore the feasibility and benefits of a 'Nurse-led Family and Network Consultation' (FNC) that seek to identify and address patients' symptoms/concerns and caregiver burden on one side and identify the resources and opportunities to ease their burdens on the other side.

To explore the impact of these nurse consultations on the nurses' perception of autonomy, self-esteem, and confidence, representing their professional identity.

Methods This is a feasibility study in two parts: 1) a sample of patients with HGG (n=30) and their caregivers (n=30) recruited for informing the study about the family function, support and caregiver burden and 2) a sample of patients with HGG (n=30) and their caregivers (n=30) recruited for intervention group (IG) with 'Nurse-led Family and Network Consultations' using pretest and posttest measures.

Part two applies a Mixed Method convergent design with a QUAL + QUAN design.

Nursing BA students at Metropolitan University College will carry out affiliated bachelor projects within CARES.

Theoretical framework Biopsychosocial Model International Classification of Functioning, Disability and Health (ICF) Use of narratives within neuro-oncology Feedback models and goal setting Symptom management theory The integrated Framework of Family System Nursing; Calgary Model Model of levels of personal and professional change

Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns.

Measurements

Test time points:

Post 1. FNC (week 1-2), post FNC 2 (week 8-10) and post FNC 3 (week 28-30) and post the 4. FNC (week 50-52).

Part 1, questionnaires for cohort patients (n=30) and caregivers:

The Caregiver Burden Scale (only caregivers) Hospital Anxiety and Depression Scale (HADS),(only caregivers)

The ICE Family Perceived Support Questionnaire (ICE-FPSQ) (caregiver and patient, individually) Psychometric development of the Iceland-Expressive Family Functioning Questionnaire (ICE-EFFQ) (caregiver and patient, individually)

Part 2, questionnaires for IG patients (n=30):

The M.D. Anderson Symptom Inventory-Brain Tumour Module (before FNC) HADS The Functional Assessment of Cancer Therapy-Brain (FACT-Br) ICE-FPSQ ICE-EFFQ

Questionnaires for IG family members (n=30):

The Caregiver Burden Scale HADS ICE-FPSQ ICE-EFFQ

Material from the FNC Written resume of each consultation (n=120)

Interviews:

Semi-structured telephone interviews with IG patients (n=30) and IG family member (n=30) post FNC 2 and post FNC 4 Focus group interview with project nurses post FNC 5 (n= 5 nurses)

Analysis The MDASI-BT, HADS, FACT-Br, the ICE-EFFQ, the ICE-FPSQ and Caregiver burden scale to be analysed separately.

Thematic analyses of interviews, field notes and resume according to Braun and Clarke.

The Mixed Methods analytic approach is interpretive integration, which merges, compares, contradicts and discusses the data sets in order to achieve analytic integration in meta-inference.

Time schedule May 2017 - December 2017: The preparatory phase February 2018 -August 2019: Cohort data collection March 2018- July 2018: Education of the project nurses August 2018 - February 2020: Intervention (1-year intervention with 6 months recruitment)

Clinical and research implications New model of care in expanded nurse-led consultations relying on FNC may be powerful way to facilitate strategies to improve symptom management, emotional well-being and reduce concerns among families.

This study will take at neurosurgical department and oncological department at Copenhagen University Hospital, Rigshospitalet in cooperation with neuro-oncological specialist team.

• Study Type: Interventional
• Enrollment (Actual): 114
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Denmark
  • Copenhagen, Denmark, 2100
    • University Hospital of Copenhagen, Rigshospitalet

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

-

Patients in the cohort (n=30) and IG (n=30) and their families will be recruited within the first week after surgery. Included are:

• Patients ≥ 18 years of age and newly diagnosed with HGG (WHO classification grade III/IV) after biopsy or operation.
• The patients and their family members and network must be able to speak and understand Danish.
• Provide informed consent

Exclusion Criteria:

• Excluded are • Patients without family or any network. There are no restrictions regarding the family members/network relation to the patient as long as the patient has accepted the person(s) as being a close relative or friend that the patient allows to participate in the FNC. Written informed consent will be obtained before discharge from the hospital or by telephone after discharge.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Family and Network support measurements; The perceived 'Family support' and 'Caregiver burden' (FNC) will be measured among 30 families. Test time points: Post 1. FNC (week 1-2), post FNC 2 (week 8-10) and post FNC 3 (week 28-30) and post the 4. FNC (week 50-52)
Experimental: Family and network consultations; Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns.	Behavioral: Family and Network Consultations; Family and Network Consultation' (FNC) seek to identify and address patients' symptoms/concerns and caregiver burden on one side and identify the resources and opportunities to ease their burdens on the other side. Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The experiences from participation in Family and network consultations (FNC)	Interviews seek the perspectives on the life situation related to the participation of FNC	At week 50 to 52

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the perceived Caregiver Burden Scale over time (only caregivers)	Self-reported caregiver burdens. The changes in frequencies will be calculated. No rating scale The scores of the 22 items of the Caregiver Burdenscale will be added together to produce the five sub-scales. The overall mean caregiver burden will be divided into three groups: low burden (1.00-1.99), medium burden (2.00-2.99) and high burden (3.00-4.00).	At week 1-2, week 8-10, week 28-30 and week 50-52
Change in the severity of depressive symptoms over time measured by the Hospital Anxiety and Depression Scale (HADS)	The self-reported prevalence and severity of depressive symptoms over time. The changes will be presented as separate scores for depressive symptoms. higher scores indicating greater likelihood of depression or anxiety.	At week 1-2, week 8-10, week 28-30 and week 50-52
Change in the severity of anxiety over time measured by the Hospital Anxiety and Depression Scale (HADS)	The self-reported prevalence and severity of anxiety over time. The changes will be presented as separate scores for depressive symptoms. higher scores indicating greater likelihood of depression or anxiety.	At week 1-2, week 8-10, week 28-30 and week 50-52
Changes in the perception of received support from nurses will be measured by the ICE Family Perceived Support Questionnaire (ICE-FPSQ) (caregiver and patient, individually)	Changes in Support from nurses. No rating scale.	At week 1-2, week 8-10, week 28-30 and week 50-52
The perceived changes of the functioning within a Family will be measured by the Psychometric development of the Iceland-Expressive Family Functioning Questionnaire (ICE-EFFQ) (caregiver and patient, individually)	Changes in Family Functioning. No rating scale.	At week 1-2, week 8-10, week 28-30 and week 50-52
The prevalence of symptoms over time will be measured by the M.D. Anderson Symptom Inventory-Brain Tumour Module	Changes in Symptoms will be reported. Each symptom is rated on a 0-10 scale (0 = ''not present'' and 10 = ''as bad as you can imagine'') over the past 24 hours. Six interference items assessing symptom-related interference in general activity, mood, work (including work around the house), relations with other people, walking, and enjoyment of life also are included in the MDASI. Each interference item is rated on a 0e10 scale (0 = ''did not interfere'' and 10 = ''interfered completely'') over the past 24 hours.	At week 1-2, week 8-10, week 28-30 and week 50-52
The quality of life will be measured by The Functional Assessment of Cancer Therapy-Brain (FACT-Br)	The self-reported quality of life related to brain cancer is measured by FACT-G. It comprises 4 sub-scales: physical well-being (PWB), social/family well-being (SWB), emotional well-being (EWB) and functional wellbeing (FWB), on a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). Moreover, the brain cancer sub-scale (BrCS) reflects issues specific for brain cancer. The highest possible score is 28 for the PWB, SWB and FWB subscales, 24 for the EWB subscale and 184 for the BrCS. FACT-Br total score is the sum of the 4 sub-scales (of the core instrument). The FACT-G total score provides a summary of the overall HRQOL across the group of patients [range 0-108] and the FACT-Br Trial Outcome Index [range 0-132] is a summary index of physical/functional outcomes. The higher the score, the better HRQOL.	At week 1-2, week 8-10, week 28-30 and week 50-52

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the perception of the nurses professional identity	Change in Professional identity	At week 28-30 and week 50-52

Collaborators and Investigators

• Sponsor: Rigshospitalet, Denmark
• Collaborators: The Novo Nordic Foundation

Publications and helpful links

General Publications

• Piil K, Laegaard Skovhus S, Tolver A, Jarden M. Neuro-Oncological Symptoms: A Longitudinal Quantitative Study of Family Function, Perceived Support, and Caregiver Burden. J Fam Nurs. 2022 Feb;28(1):43-56. doi: 10.1177/10748407211029986. Epub 2021 Jul 21.

Study record dates

Study Major Dates

• Study Start (Actual): April 9, 2018
• Primary Completion (Actual): July 1, 2020
• Study Completion (Actual): November 1, 2023

Study Registration Dates

• First Submitted: January 5, 2018
• First Submitted That Met QC Criteria: March 1, 2018
• First Posted (Actual): March 8, 2018

Study Record Updates

• Last Update Posted (Actual): November 28, 2023
• Last Update Submitted That Met QC Criteria: November 27, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Glioma
• Other Study ID Numbers: CARES

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No